Successful Treatment of Candida parapsilosis Fungemia in Two Preterms with Voriconazole.

Altuncu E., Bilgen H. S., Soysal A., ÖZEK E.

Case reports in pediatrics, vol.2015, pp.402137, 2015 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 2015
  • Publication Date: 2015
  • Doi Number: 10.1155/2015/402137
  • Journal Name: Case reports in pediatrics
  • Journal Indexes: Emerging Sources Citation Index (ESCI)
  • Page Numbers: pp.402137
  • Marmara University Affiliated: Yes

Abstract

Herein, we report two preterms with invasive candidiasis refractory to liposomal amphotericin B (AMB) treatment in spite of low MIC levels (MIC: 0.5 mcg/mL). Both of the patients' blood cultures were persistently positive for C. parapsilosis despite high therapeutic doses (AMB: 7mg/kg per day). After starting voriconazole blood cultures became negative and both of the patients were treated successfully without any side effects. In conclusion, although it is not a standard treatment in neonatal patients, our limited experience with these patients suggests that voriconazole appears to be a safe antifungal agent to be used in critically ill preterm infants with persistent fungemia despite AMB treatment.